TSXV:RKV - Post Discussion
Post by
Betteryear2 on Nov 17, 2021 8:06am
InvestmentPitch Media Video
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2021) - Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, has been selected to join a three year research program funded by the St. Baldrick's Foundation Martha's BEST Grant for All. The US$975,000, or CDN$1,297,000, research program is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.
https://www.youtube.com/watch?v=5IKsKz4pXbs
Be the first to comment on this post